相关实验视频

Updated: Jun 8, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

112

探索易于访问的神经生理学生物标志物来预测阿尔茨海默病的进展:一个系统性审查

Matteo Costanzo1,2, Carolina Cutrona1, Giorgio Leodori1,3

  • 1Department of Human Neurosciences, Sapienza University of Rome, Viale dell'Università 30, Rome, 00185, RM, Italy.

Alzheimer's research & therapy
|November 4, 2024
PubMed
概括

像EEG和TMS这样的神经生理生物标志物在预测阿尔茨海默病 (AD) 进展方面表现有前途. 需要进一步的研究来验证这些具有成本效益的工具,以更早地诊断和理解AD.

关键词:
阿尔茨海默氏症是阿尔茨海默氏症的疾病生物标志物 生物标志物电脑电图 (电脑电图) 是一种脑电图.与事件相关的潜力与事件相关的潜力神经生理学 神经生理学通过骨磁刺激进行磁性刺激.

更多相关视频

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.8K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.3K

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165